Add To Watchlist
Share URL
About The Company
CEO
Mr. Kristian Villumsen
Market Cap
25.46 Billion USD
Sector
Healthcare
Website
https://www.coloplast.comDescription
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.
Read More
Overview
Value
9
Growth
32
Health
44
Management
21
Analyst Opinion
91
Total
39
All Scores Out Of 100
Best Features
- Liked by analysts
- Has strong dividend growth 0
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- There is a history of diluting shareholders
- Has a high level of debt
- Does not hold enough liquid assets to cover short term liabilities
- No margin of safety at their current market price
- Poor earnings and cashflow growth
- Price-to-earnings ratio of 52.3 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Latest News
Coloplast A/S (CLPBF) Q1 2023 Earnings Call Transcript
Seeking Alpha | 15:10 Fri 3 Feb 2023
Read More →
Coloplast A/S (CLPBF) CEO Kristian Villumsen on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha | 22:19 Wed 17 Aug 2022
Read More →
The Scandinavian Shopping List In A Time Of Bargains
Seeking Alpha | 22:04 Fri 3 Jun 2022
Read More →
Market Peers
CLPBY
Key Figures
PE Ratio (TTM)
52.34
Margin Of Safety (DCF)
-43.36%
Revenue Growth (5 Year Average)
4.76%
Ratings Consensus
Strong Buy
Share Buybacks
-0.07%
Dividend Yeild (TTM)
2.22%
Valuation
Value Score
9
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 56.6 USD ✔
Current Price: 12.3 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
52.34x
Free Cashflow Yeild
1.23%
PE/Earnings Growth
N/A
Price/Book
0.75x
Growth
Growth Score
32
- ✔ Revenue growth has improved this yeara
- ✘ 5 Year Average Revenue growth of 4.76% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 8.16% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 0.79% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
4.76%
Earnings Growth
8.16%
Cashflow Growth
0.79%
Health
Health Score
44
Altman Z Score
2.03
Piostroski Score
7.00
Debt/Equity
2.26x
Current Assets/Liabilities
N/Ax
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
21
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✘ Return-on-capital-employed of N/A is lower than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Return-on-equity of N/A is lower than the market average (15%)
Average Buybacks/Dilution
-0.07%
Recent Buybacks/Dilution
-0.23%
5 Year Price Volitility
21.82%
Return On Assets
N/A
Return On Capital Employed
N/A
Return On Equity
N/A
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
91
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Coloplast A/S
Currency
USD
Beta
0.221568
Vol Avg
84416
Ceo
Mr. Kristian Villumsen
Cik
0001294325
Cusip
Exchange
Other OTC
Full Time Employees
14572
Industry
Medical Instruments & Supplies
Sector
Healthcare
Ipo Date
2014-01-13
Address
Holtedam 1-3
City
Humlebæk
State
Country
DK
Zip
3050
Phone
45 49 11 11 11
All financial data provided by FMP